Biotech makes a splash in HK as Ascletis prices IPO

John Loh

July 26, 2018 10:00 am

microscope — Scientist hands with microscope close-up shot in the laboratory | Konstantin Kolosov/kkolosov - Fotolia

Ascletis Pharma priced its Hong Kong IPO in the middle of expectations on Wednesday, raising HK$3.1bn ($400m) from the city’s inaugural biotechnology offering.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs China Merchants Securities Co Equity China Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets SRI Goldman Sachs

JL

John Loh